Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Catalyzing Sarcopenia Drug Development: Identifying Outcomes, Defining Disease

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.

You may also be interested in...



Can Drugs Really Treat Sarcopenia? Some Patients Are Doubtful

Companies developing treatments for sarcopenia ‘have no idea what they're doing’, according to Ray Lipicky, a former director of the FDA’s Cardio-Renal Drug Products Division who spoke as a patient at the US agency’s sarcopenia drug development meeting.

A Shift In Thinking: FDA Moves Toward Easier Neurofibromatosis Endpoints

Volumetric imaging gains favor as a primary endpoint, along with single-arm studies, potentially creating a faster path to drug approval in the rare disease.

Nascent Sarcopenia Pipeline’s First Target Is Myostatin

Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel